Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages 138-146

  Chen, Y C ^a   Huang, S F ^b   Chu, C M ^a   Liaw, Y F ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

alanine aminotransferase; chronic hepatitis B; hepatitis B surface antigen; inactive hepatitis B surface antigen carriers

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DISEASE COURSE; DNA DETERMINATION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; ISHAK FIBROSIS SCORE; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SEROCONVERSION; SEX DIFFERENCE;

ADOLESCENT; ADULT; BIOPSY; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TRANSAMINASES; YOUNG ADULT;

EID: 84855851855     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01450.x     Document Type: Article

References (35)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107. (Pubitemid 38365759)
2. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
3. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcomes after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527.
4. Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-834. (Pubitemid 38721324)
5. Chen YC, Chu CM, Liaw YF,. Age-specific prognosis following spontaneous HBeAg seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-444.
6. Lok AS, Heathcote EJ, Hoofnagle JH,. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-1853. (Pubitemid 32523500)
7. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum HBV DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36: 543-546. (Pubitemid 34407344)
8. Chu CJ, Hussain M, Lok ASF,. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-1415. (Pubitemid 35407438)
9. Manesis EK, Papatheodoridis GV, Sevastianos V, et al. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98: 2261-2267. (Pubitemid 37305368)
10. Lin CL, Liao LY, Liu CJ, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007; 45: 1193-1198.
11. Feld JJ, Ayers M, El-Ashry D, et al. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007; 46: 1057-1070. (Pubitemid 350147802)
12. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, et al. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008; 15: 434-441. (Pubitemid 351677546)
13. Zacharakis G, Koskinas J, Kotsiou S, et al. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol 2008; 49: 884-891.
14. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decision in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-1459.
15. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686. (Pubitemid 43374518)
16. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
17. Hadziyannis SJ,. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatol Int 2007; 1: 281-284.
18. Lok ASF, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
19. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific Consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
20. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513.
21. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
22. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
23. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
24. Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009; 49: 1859-1867.
25. Ikeda K, Arase Y, Saitoh S, et al. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 2006; 119: 977-985. (Pubitemid 44634315)
26. Chu CM, Liaw YF,. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-1699.
27. Chu CM, Chen YC, Tai DI, et al. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol 2010; 8: 535-540.
28. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-1089.
29. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
30. Liaw YF, Lin SM, Chen TJ, et al. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomised controlled trial. J Hepatol 1994; 20: 175-180.
31. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
32. Ni YH, Chang MH, Chen PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007; 132: 2340-2345.
33. Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008; 29: 106-112.
34. Nguyen MH, Garcia RT, Trinh HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol 2009; 104: 2206-2213.
35. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.